SAT-039 clinical and demographic characteristics of a cohort of adults IN TREATMENT WITH a biosimilar HUMAN GROWTH HORMONE

Abstract Disclosure: A. Soto: None. A. Jimenez sanchez: None. M. Dios Fuentes: None. P. Remon-Ruiz: None. E. Venegas moreno: None. GOAL: • To describe the clinical and socio-demographic characteristics of a cohort of 53 adults under growth hormone (GH) treatment in our center. MATERIALS & METHODS: • Transversal study. • Variables were retrospectively collected from the digital health record of the Virgen del Rocío University Hospital in August 2023. • Numerical variables are expressed as mean (standard deviation). Statistical significance was designated as a p-value < 0.05. • Elders were defined as those ≥ 65 years old. • Quality of life was assessed via the Quality of Life-Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) questionnaire. • IGF-1 reference values from our hormone laboratory are the following: /div> Results: • 53 patients under treatment, of which 7 were elders. • 49.35 (19.68) years old • 22 (41.51%) men, 31 (58.49%) women. /div> • Dosing: - Treatment days per week: 6.37 (1.18). - Dose per day: 0.342 (0.199) mg/day. - Dose per kg and day: 0.004 (0.003) mg/kg/day. • Lipid panel: - Total cholesterol 194.79 (32.25) mg/dL. - HDL-cholesterol 57.5 (17.1) mg/dL. - Triglycerides 131.5 (77.1) mg/dL. • Basic anthropometry: - Height 1.659 (0.102) m. - Weight 83.85 (18.41) kg. - BMI 30.55 (6.76) kg/m2. BMI in elders: 30.65 kg/m2 vs young adults: 29.91 kg/m2 (p-value=0.732). - Waist-hip ratio 0.906 (0.111). Correlation with IGF-1: 0.052 (p-value=0.706). • IGF-1: 142.73 (50.77) pg/mL. 7 (13.2%) patients were underdosed, all of which were elders. • Quality of life (QoL): - 9.9 (8,4) points. - QoL in men: 6 (15), women 12 (13) points (p-value=0.196). - QoL in elders: 10.333, young adults: 7.285 (p-value=0.298). - Correlation with IGF-1: -0.035 (p-value=0.800). - Correlation with mg per day: -0.248 (p-value = 0.075) and per kg: -0.206 (p-value=0.155). • DEXA: - Femoral neck bone mineral density (BMD): -1.16 (0.89) SDs. Correlation with IGF-1: 0.107 (p-value=0.600). - DEXA total lumbar spine BMD: -0.88 (1.27) SDs. Correlation with IGF-1: -0.151 (p-value=0.449). ConclusionS: • Pituitary tumors were the first indication for growth hormone in adults, followed by traumatic brain injury. • A minority of patients were elders. • IGF-1 levels were not correlated with neither quality of life, bone mineral density nor waist-to-hip ratio. Presentation: Saturday, July 12, 2025